- advertisement -


Discussion in 'Adults with Type 2' started by Ellen, Jan 5, 2006.

  1. Ellen

    Ellen Senior Member

    Oct 22, 2005
    WASHINGTON, Jan 5 (Reuters) - The U.S. Food and Drug Administration and GlaxoSmithKline Plc (GSK.N: Quote, Profile, Research)(GSK.L: Quote, Profile, Research) have warned doctors about new or worsening eye complications in patients taking three of its diabetes drugs, according to a letter made public on Thursday.
    In most cases, patients taking rosiglitazone -- sold as Avandia, Avandamet and Avandaryl -- reported swelling of the eye known as macular edema, the company said in the letter sent last month.
    Such reports were "very rare," the letter said, but did not offer a figure. A company spokeswoman did not immediately return a call seeking comment.
    "In some cases, the macular edema resolved or improved following discontinuation of therapy and in one case, macular edema resolved after dose reduction," the letter said.
    Company officials said they proposed including a precaution in product information for doctors and in brochures for patients, according to the letter posted on the FDA's Web site at www.fda.gov/medwatch/safety/2006/safety06.htm#Avandia.
    Shares of Glaxo were off 3 cents at $51.92 in afternoon trading on the New York Stock Exchange after earlier closing up less than 1 percent in London.
  2. jstump7697

    jstump7697 Approved members

    Jun 4, 2007
    i talked to my doctor and they said as long as i am not having any heart problems like shortness of breathe, etc that i do not need to worry unless the FDA pulls it off the shelves. They are concerned but the medicine works for me.

Share This Page

- advertisement -

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.
    Dismiss Notice